CD‐1db/db mice: A novel type 2 diabetic mouse model with progressive kidney fibrosis

To establish novel therapies to combat diabetic kidney disease, a human disease‐relevant animal model is essential. However, a type 2 diabetic mouse model presenting progressive kidney fibrosis has not yet been established. Kidneys of streptozotocin‐induced diabetic CD‐1 mice showed severe fibrosis compared with other backgrounds of mice associated with the suppression of antifibrotic peptide N‐acetyl‐seryl‐aspartyl‐lysyl‐proline. The BKS background (BKSdb/db) is often utilized for diabetic kidney disease research; the kidney fibrosis in the BKSdb/db phenotype is minimal.

[1]  M. Haneda,et al.  N-Acetyl-seryl-aspartyl-lysyl-proline is a potential biomarker of renal function in normoalbuminuric diabetic patients with eGFR ≥ 30 ml/min/1.73 m2 , 2019, Clinical and Experimental Nephrology.

[2]  Daisuke Koya,et al.  Rodent models of diabetic nephropathy: their utility and limitations , 2016, International journal of nephrology and renovascular disease.

[3]  Y. Ishigaki,et al.  Effect of Antifibrotic MicroRNAs Crosstalk on the Action of N-acetyl-seryl-aspartyl-lysyl-proline in Diabetes-related Kidney Fibrosis , 2016, Scientific Reports.

[4]  R. MacIsaac,et al.  Clinical predictive factors in diabetic kidney disease progression , 2016, Journal of diabetes investigation.

[5]  M. Haneda,et al.  Oral Administration of N-Acetyl-seryl-aspartyl-lysyl-proline Ameliorates Kidney Disease in Both Type 1 and Type 2 Diabetic Mice via a Therapeutic Regimen , 2016, BioMed research international.

[6]  D. Koya,et al.  Interactions of DPP-4 and integrin β1 influences endothelial-to-mesenchymal transition. , 2015, Kidney international.

[7]  I. D. de Boer,et al.  Diabetic Kidney Disease: A Report From an ADA Consensus Conference , 2014, Diabetes Care.

[8]  Y. Ishigaki,et al.  Linagliptin-Mediated DPP-4 Inhibition Ameliorates Kidney Fibrosis in Streptozotocin-Induced Diabetic Mice by Inhibiting Endothelial-to-Mesenchymal Transition in a Therapeutic Regimen , 2014, Diabetes.

[9]  Takahisa Yamada,et al.  Diabetic Complications in Obese Type 2 Diabetic Rat Models , 2014, Experimental animals.

[10]  D. Koya,et al.  N-acetyl-seryl-aspartyl-lysyl-proline: a valuable endogenous anti-fibrotic peptide for combating kidney fibrosis in diabetes , 2014, Front. Pharmacol..

[11]  Y. Ishigaki,et al.  N-acetyl-seryl-aspartyl-lysyl-proline Inhibits Diabetes-Associated Kidney Fibrosis and Endothelial-Mesenchymal Transition , 2014, BioMed research international.

[12]  G. Russo,et al.  Kidney dysfunction and related cardiovascular risk factors among patients with type 2 diabetes. , 2014, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[13]  R. D. de Boer,et al.  Sodium restriction on top of renin–angiotensin–aldosterone system blockade increases circulating levels of N-acetyl-seryl-aspartyl-lysyl-proline in chronic kidney disease patients , 2013, Journal of hypertension.

[14]  Li-jun Ma,et al.  Thymosin β4 and its degradation product, Ac-SDKP, are novel reparative factors in renal fibrosis , 2013, Kidney international.

[15]  C. D. di Gioia,et al.  Renal Antifibrotic Effect of N-Acetyl-Seryl-Aspartyl-Lysyl-Proline in Diabetic Rats , 2013, American Journal of Nephrology.

[16]  D. Batlle,et al.  New Experimental Models of Diabetic Nephropathy in Mice Models of Type 2 Diabetes: Efforts to Replicate Human Nephropathy , 2012, Experimental diabetes research.

[17]  A. Riches,et al.  Overexpression of the natural tetrapeptide acetyl‐N‐ser‐asp‐lys‐pro derived from thymosin β4 in neoplastic diseases , 2010, Annals of the New York Academy of Sciences.

[18]  S. Perlini,et al.  Prevention of myocardial fibrosis by N-acetyl-seryl-aspartyl-lysyl-proline in diabetic rats. , 2010, Clinical science.

[19]  R. Kalluri,et al.  Renal Fibrosis and Glomerulosclerosis in a New Mouse Model of Diabetic Nephropathy and Its Regression by Bone Morphogenic Protein-7 and Advanced Glycation End Product Inhibitors , 2007, Diabetes.

[20]  J. Wdzieczak‐Bakala,et al.  The tetrapeptide acetyl‐serine‐aspartyl‐lysine‐proline improves skin flap survival and accelerates wound healing , 2006, Wound repair and regeneration : official publication of the Wound Healing Society [and] the European Tissue Repair Society.

[21]  M. Haneda,et al.  N-acetyl-seryl-aspartyl-lysyl-proline ameliorates the progression of renal dysfunction and fibrosis in WKY rats with established anti-glomerular basement membrane nephritis. , 2006, Journal of the American Society of Nephrology : JASN.

[22]  K. Isshiki,et al.  N-acetyl-seryl-aspartyl-lysyl-proline prevents renal insufficiency and mesangial matrix expansion in diabetic db/db mice. , 2005, Diabetes.

[23]  M. Cavasin,et al.  Prolyl Oligopeptidase Is Involved in Release of the Antifibrotic Peptide Ac-SDKP , 2004, Hypertension.

[24]  T. Sugimoto,et al.  N-Acetyl-seryl-aspartyl-lysyl-proline inhibits TGF-beta-mediated plasminogen activator inhibitor-1 expression via inhibition of Smad pathway in human mesangial cells. , 2003, Journal of the American Society of Nephrology : JASN.

[25]  Daniel C. Marcus,et al.  Age-Related Changes in Cochlear Endolymphatic Potassium and Potential in CD-1 and CBA/CaJ Mice , 2003, Journal of the Association for Research in Otolaryngology.

[26]  O. Carretero,et al.  Effect of N-Acetyl-Seryl-Aspartyl-Lysyl-Proline on DNA and Collagen Synthesis in Rat Cardiac Fibroblasts , 2001, Hypertension.

[27]  S. Chua,et al.  Spontaneous mutation in the db gene results in obesity and diabetes in CD-1 outbred mice. , 2000, American journal of physiology. Regulatory, integrative and comparative physiology.

[28]  K. Clément,et al.  A mutation in the human leptin receptor gene causes obesity and pituitary dysfunction , 1998, Nature.

[29]  S. O’Rahilly,et al.  Congenital leptin deficiency is associated with severe early-onset obesity in humans , 1997, Nature.

[30]  Per Capita,et al.  About the authors , 1995, Machine Vision and Applications.

[31]  C. Grillon,et al.  Involvement of thymosin β4 and endoproteinase Asp‐N in the biosynthesis of the tetrapeptide AcSerAspLysPro a regulator of the hematopoietic system , 1990, FEBS letters.

[32]  Giuseppe Remuzzi,et al.  Sodium intake, ACE inhibition, and progression to ESRD. , 2012, Journal of the American Society of Nephrology : JASN.

[33]  渋谷 和之.  N-acetyl-seryl-aspartyl-lysyl-proline prevents renal insufficiency and mesangial matrix expansion in diabetic db/db mice , 2005 .